Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD.

BMC Cancer. 2009 Jul 27;9:253. doi: 10.1186/1471-2407-9-253.

2.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85. Epub 2007 Mar 6.

PMID:
17343903
3.

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD.

J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.

4.

Mammaglobin B expression in human endometrial cancer.

Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. Epub 2007 Nov 16.

PMID:
18021217
5.

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD.

Eur J Cancer. 2010 Mar;46(5):944-53. doi: 10.1016/j.ejca.2009.12.019. Epub 2010 Jan 8.

PMID:
20060709
6.

Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.

Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, Diamandis EP.

Clin Biochem. 2003 Mar;36(2):135-43.

PMID:
12633763
7.

Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.

Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex LV, Sweep FC.

J Clin Oncol. 2004 Feb 15;22(4):691-8.

PMID:
14966093
8.

Mammaglobin and lipophilin B expression in breast tumors and their lack of effect on breast cancer cell proliferation.

Sjödin A, Ljuslinder I, Henriksson R, Hedman H.

Anticancer Res. 2008 May-Jun;28(3A):1493-8.

9.

CD44 expression indicates favorable prognosis in epithelial ovarian cancer.

Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM.

Clin Cancer Res. 2003 Nov 1;9(14):5318-24.

10.

Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.

Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H.

Cancer Invest. 2008 Mar;26(2):185-92. doi: 10.1080/07357900701638343.

PMID:
18259951
11.

Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.

Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, Xu H, Shou C.

Pathol Oncol Res. 2009 Dec;15(4):555-60. doi: 10.1007/s12253-009-9153-1. Epub 2009 Feb 27.

PMID:
19247814
12.
13.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2004 Dec 1;22(23):4700-10. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15505275
14.

PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.

Ma R, Ye X, Cheng H, Ma Y, Cui H, Chang X.

Gynecol Oncol. 2015 Jun;137(3):546-52. doi: 10.1016/j.ygyno.2015.02.022. Epub 2015 Feb 28.

PMID:
25735255
15.

Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.

Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.

Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.

16.

Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.

Lee YK, Park NH, Lee H.

Exp Mol Med. 2015 Nov 20;47:e195. doi: 10.1038/emm.2015.85.

17.

Overexpression of ASAP1 is associated with poor prognosis in epithelial ovarian cancer.

Hou T, Yang C, Tong C, Zhang H, Xiao J, Li J.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):280-7. eCollection 2014.

18.

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV.

Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19.

PMID:
22258792
19.

High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.

Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX.

Eur J Surg Oncol. 2012 Jun;38(6):523-30. doi: 10.1016/j.ejso.2012.02.180. Epub 2012 Mar 21.

PMID:
22440742
20.

The potential prognostic value of cathepsin D protein in serous ovarian cancer.

Chai Y, Wu W, Zhou C, Zhou J.

Arch Gynecol Obstet. 2012 Aug;286(2):465-71. doi: 10.1007/s00404-012-2318-2. Epub 2012 Apr 3.

PMID:
22476353

Supplemental Content

Support Center